logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Fdas Drug Review Process And The Package Label Strategies For Writing Successful Fda Submissions Brody

  • SKU: BELL-7119640
Fdas Drug Review Process And The Package Label Strategies For Writing Successful Fda Submissions Brody
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

Fdas Drug Review Process And The Package Label Strategies For Writing Successful Fda Submissions Brody instant download after payment.

Publisher: Academic Press
File Extension: PDF
File size: 7.15 MB
Pages: 653
Author: Brody, Tom
ISBN: 9780128146477, 0128146478
Language: English
Year: 2018

Product desciption

Fdas Drug Review Process And The Package Label Strategies For Writing Successful Fda Submissions Brody by Brody, Tom 9780128146477, 0128146478 instant download after payment.

FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. See back cover. 

Related Products